Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence

Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence

Abstract Background Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A‐subunit deficiency (FXIII‐A CD). Recombinant factor XIII‐A2 (rFXIII‐A2) was extensively evaluated in the mentor trials. Objective To assess real‐world safety and treatment effectiveness of rFXIII...

Full description

Bibliographic Details
Main Authors: Lone Hvitfeldt Poulsen, Bryce A. Kerlin, Giancarlo Castaman, Angelo Claudio Molinari, Marzia Menegatti, Diane Nugent, Sohan Dey, May‐Lill Garly, Manuel Carcao
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
factor XIII
long‐term care
recombinant factor XIII‐A2
safety
treatment effectiveness
Online Access:https://doi.org/10.1002/rth2.12628

Internet

https://doi.org/10.1002/rth2.12628

Similar Items